Title: Biliary Duct Hamartomas: A Systematic Review

Abu Baker Sheikh¹, Rahul Shekhar², Nismat Javed³, Katarina Leyba⁴, Abdul Ahad Ehsan Sheikh⁵, Shubhra Upadhyay⁶, Devika Kapuria⁷, Christopher Cormier⁸, Tarun Rustagi⁹

1. MD, Resident Physician, University of New Mexico Health Sciences Center, Department of Internal Medicine, Albuquerque, NM, USA. Email: absheikh@salud.unm.edu.
2. MD, Assistant Professor, Division of Hospital Medicine, University of New Mexico Health Sciences Center, Department of Internal Medicine, Albuquerque, NM, USA. Email: rahul547843@gmail.com.
3. MBBS, Shifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan. Email: nismatjaved@gmail.com.
4. Medical Student, University of New Mexico, Department of Internal Medicine, Albuquerque, NM, USA. Email: katarinaleyba@gmail.com.
5. MD, Resident Physician, The Wright Center for Graduate Medical Education, Department of Internal Medicine, Scranton, PA, USA. Email: abdualahad.esn@gmail.com.
6. MD, Resident Physician, University of New Mexico Health Sciences Center, Department of Internal Medicine, Albuquerque, NM, USA. Email: shubhra046762@gmail.com.
7. MD, Clinical Fellow Department of Gastroenterology and Hepatology, University of New Mexico Health Science Center, Albuquerque, NM, USA. Email: devika.kapurja@salud.unm.edu.
8. MD, Resident Physician Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA. Email: cmcmormier@salud.unm.edu.
9. MD, Interventional Endoscopist & Assistant Professor Division of Gastroenterology and Hepatology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA. Email: trustagi@salud.unm.edu.

Corresponding author:

Abu Baker Sheikh

MSC 10-5550, 1 University of New Mexico

Albuquerque, NM 87131

Contact: 631-633-4125

Email: absheikh@salud.unm.edu.

Short Title: Biliary Duct Hamartomas: An Updated Review

Conflicts of Interest and Source of Funding: The authors have no conflict of interest and sources of funding to declare.

ABSTRACT

Biliary duct hamartomas are benign lesions of intrahepatic bile ducts. Oftentimes an incidental finding on imaging, these lesions can pose a diagnostic dilemma because of their overlapping features with malignant masses. We performed a structured systematic review of literature and identified 139 cases of biliary duct hamartomas. Patient demographics, clinical presentation with key laboratory and imaging findings, diagnostic modalities, management strategies, and outcomes were analyzed and systematically summarized. The systematic review is aimed to help with better understanding of biliary duct hamartomas and its principal features.

Key-words: Biliary duct hamartomas; clinical presentation; VMC; imaging

INTRODUCTION

Biliary duct hamartomas, or “von Meyenberg complexes,” are benign malformations of intrahepatic bile ducts.^{1,2} They are often found incidentally on imaging or laparotomy, and although clinically benign, they can mimic malignant lesions, and present with clinical symptoms that prompts a lengthy diagnostic workup and even surgical intervention. The rare nature of this condition as well as heterogenous clinical presentation can make management challenging^{1,3}, and it is therefore important to recognize biliary hamartomas and distinguish them from other pathologies.

Overall, biliary hamartomas are relatively rare findings that result from the failure of involution of embryonic bile ducts, typically malformations of smaller interlobular bile ducts. Their estimated prevalence ranges from 0.6-5.6% on autopsy and is around 1.0% on imaging.^{4,5} Although biliary duct hamartomas have been described in children, they most commonly affect individuals age 35 and older.¹ They are more common in patients with polycystic liver disease and polycystic kidney disease,⁶ and studies have found that they occur at increased frequency in patients with cirrhosis, indicating that there may be some component of environmental exposure involved in their pathogenesis.^{1,7}

Most biliary hamartomas are asymptomatic, although they can uncommonly cause fever, jaundice or abdominal pain. Similarly, most patients present with an unremarkable clinical exam and normal lab results, but rare elevations in transaminases, alkaline phosphatase or gamma-glutamyl transferase (GGT) levels can occur.¹ While their clinical course is generally benign, as with other ductal plate malformations, biliary hamartomas do pose a small risk of malignant transformation to intrahepatic cholangiocarcinoma or, less frequently, hepatocellular carcinoma.⁸ Given the marked differences between the management of biliary hamartomas and other,

similar-appearing diseases, it is important to fully characterize them in order to facilitate accurate diagnosis and optimal management. Within this context, our systematic review aims to provide a comprehensive clinical profile of biliary duct hamartomas and an up to date overview of all cases reported in the literature to identify salient and distinguishing features.

METHODS

Protocol development and systematic review registration

We developed the protocol for this review after consensus with all the reviewers and subject experts per PRISMA guidelines. After protocol preparation and registration on PROSPERO (CRD42021230745), data search was performed as below.

Search strategy

Keywords (including all commonly used abbreviations of these terms) used in the search strategy were as follows: "Biliary hamartomas" OR "Von Meyenburg Complexes" OR "Biliary duct hamartomas" OR "Hamartomas AND biliary " OR "Multiple biliary hamartomas" OR "Multiple biliary duct hamartomas".

Data extraction (selection and coding)

We screened PubMed, Web of Science and CINAHL databases and articles published in the English language were included in the systemic review over the last 30 years. On the initial search, 163 articles on PubMed, 33 on Web of Science (excluding Medline) and 63 on CINAHL (excluding Medline) were included. After the initial search, duplicates were removed, and we imported all included search study into EndNote online software (Figure 1). Two independent reviewers (NJ and ABS) screened remaining studies for the inclusion based on inclusion criteria, and researchers were blinded to each other's decisions. Rayyan software and Mendeley desktop were used. The screening was done via reading the abstract and if needed by reading full-text articles. Studies published in the English language or English translation as well as available for viewing were included in the initial review. Once the initial screening was done, two independent reviewers (SU and AAES) reviewed the full-text article for final inclusion. Reviewers were blinded to each other's decisions, and a third reviewer resolved any dispute (RS).

Data was extracted from study documents, including information about study design and methodology, participant demographics and baseline characteristics, study country, publication journal, clinical presentation, symptoms, laboratory data, imaging data, intervention, treatment, clinical outcomes, morbidity, and mortality.

One reviewer did data extraction, and another reviewer cross-checked the extracted data for accuracy and completeness. Any disagreements between individual judgements were resolved via the third reviewer. Attempts were made to obtain any missing data from study corresponding investigators via email. If data could not be obtained, that study was excluded from the analysis on a case-by-case basis. Publications that were not peer-reviewed were excluded from this study. The preliminary data was entered and recorded in an excel spreadsheet. The final analysis included 82 studies.

Risk of bias (quality) assessment

Quality assessment of all the included studies was assessed using the methodological quality and synthesis of case series and case reports described by Murad et al. (2018).⁹ (Table 1 and Table 2)

According to this tool, four broad perspectives to assess the quality; selection of the study groups, ascertainment of the observed outcome, causality of the observed outcome and case reporting

Strategy for data synthesis

For statistical analysis, we used IBM SPSS Statistics version 21 (IBM, Armonk, NY, USA). Based on the distribution of values, continuous data were expressed as mean $\pm$ standard deviation. Qualitative variables were expressed as frequency and percentages.

RESULTS

To date, 139 patients with bile duct hamartomas have been reported in the literature, including 68 case reports and 15 case series.

These 139 patients were included in the analysis. Summarized data from all analyzed cases are reported in Tables 3, 4 and 5.^{2, 7, 8, 10-89}

Patient Demographics

Patient ages ranged from 17 to 88 years at time of diagnosis, and the mean age of all patients in this analysis was 55 $\pm$ 13 years. A slight male predominance was noted, with males comprising 63.3% (88 vs 51) of all cases reported.

Comorbidities

Of 139 published cases, 48.9% had an underlying comorbidity reported. The most frequently reported comorbidity was cancer, which was present in 12.9% of patients. Among those cases, gastrointestinal cancers (e.g., esophageal cancers, gastric cancer, common bile duct cancer and colorectal cancer) were the most common, accounting for 12 of 18, or 66.7%, of underlying malignancies in this analysis. Comorbid malignancies of the breast, prostate, lung and thyroid were also reported.

Viral hepatitis was reported in 8.6% of patients in this analysis, with hepatitis B accounting for 7 of 12 cases (58.3%), and hepatitis C accounting for 5 of 12 of cases (41.7%). Additionally, 8.6% of patients were reported to have underlying hypertension, and 5.0% of patients had type 2 diabetes mellitus. Other reported comorbidities include tobacco use (4.3%), alcohol use (3.6%), hemochromatosis (1.4%) and tuberculosis (1.4%).

Clinical Presentation

Only 36% of patients in this analysis were symptomatic at presentation, suggesting that majority (nearly 2/3) patients are asymptomatic at the time of presentation. Among patients who were symptomatic, abdominal pain was the most common symptom reported by 22.3% (31 of 139) of all patients and ranged from vague abdominal pain and discomfort to localized epigastric or right hypochondrial pain. Other commonly reported symptoms included: fever (18.0%), weight loss (14.0%), and jaundice (14.0%). Less frequently reported clinical features include abdominal distension and upper and lower gastrointestinal bleeding. The time from development of symptoms to presentation was variably reported among studies and ranged from one day to ten years.

Although clinical exam was also variably reported among studies, a positive Murphy's sign and right hypochondrial tenderness to palpation were common among patients for whom a physical exam was reported (9 out of 26, or 34.6%), especially among patients who presented with abdominal pain. Hepatomegaly and splenomegaly were reported in a relatively small portion of patients with documented physical exams (19.2% and 13.6%, respectively).

Laboratory Findings

Laboratory data, mainly alanine or aspartate transaminases (ALT/AST), was reported for 66 of 139 patients in this analysis. Of those 66 patients, 33.3% had some degree of elevated transaminase levels. Laboratory data for gamma-glutamyl transferase (GGT) and alkaline phosphatase levels (ALP) were reported for 71 patients and 42.2% of the patients (30 of 71) were reported to have elevated gamma-glutamyl transferase (GGT) or alkaline phosphatase levels. Laboratory data for bilirubin was reported for 60 patients in the analysis. Of these 60 patients, 15 patients (25.0%) had hyperbilirubinemia. Other reported laboratory abnormalities include hypoalbuminemia, elevated C-reactive protein (CRP) and hematologic abnormalities such as anemia, leukocytosis, leukopenia and thrombocytopenia.

Tumor marker data were reported for 42 of 139 patients. The vast majority (85.7%) did not have any tumor marker elevations. Four patients (9.5%) were found to have elevated levels of carbohydrate antigen-19 (CA-19), a tumor marker associated with gastrointestinal malignancies, especially pancreatic malignancies.^{88, 90} One patient (2.4%) was found to have elevated levels of alpha

fetoprotein (AFP), a tumor marker associated with liver and testicular cancers,^{90, 91} and one patient (2.4%) was found to have elevations in carcinoembryonic antigen (CEA), which is a tumor marker associated with malignancies in multiple organ systems, including the gastrointestinal system.⁹⁰

Imaging

122 of 139 patients in this analysis underwent some form of abdominal imaging whereas the rest of the patients were diagnosed by biopsy results. 60 (43.2%) underwent ultrasound imaging, 69 (49.6%) underwent computed tomography (CT) scans, and 81 (58.2%) underwent magnetic resonance imaging (MRI) scans. Radiographic abnormalities were detected by all imaging modalities. The suspected lesions expected to be benign biliary duct hamartomas were hypoechogenic in 50.0% (30/60) of ultrasounds, hyperechogenic in 21.7% (13/60) whereas mixed echogenicity was seen in 28.3% (17/60). Similarly, for the same suspected lesions, CT radiography revealed hypointensity and hyperintensity in 81.2% (56/69) and 13.0% (9/69) of patients, respectively, whereas, 5.8% of the patients (4/69) had mixed intensity signals from the lesions. 40 CT scans utilized contrast, and of those, contrast-enhancement was present in 32.5% of images. Studies in this analysis reported both T1-weighted and T2-weighted MRI scans. Of the 81 T1-weighted scans performed for the suspected lesions, 96.3% reported hypointensity and 3.7% reported hyperintensity. In comparison, 6.2% of the 80 T2-weighted scans, for the benign lesions, reported hypointensity and 93.8% revealed hyperintensity. 41 MRI scans utilized contrast, and of those, 41.5% reported contrast-enhancement. Several patients also underwent magnetic resonance cholangiopancreatography (MRCP), which revealed hepatic lesions or cysts with no connection to the biliary tree. However on

imaging, it was noted that in 3 cases, ultrasound revealed dilated biliary ducts. Furthermore, it was noted that in one case, CT scan revealed dilated biliary ducts. Similarly, the same finding was noted by MRI in 4 cases.

Lesion Characteristics

Size and location of the lesions of interest were reported on radiology for 44.6% and 48.2% of cases, respectively. Of lesions for which size data is available, 53.2% were found to be <1cm in size. 22 of 67 lesions (32.8%) were found to be uniformly distributed throughout the liver, whereas 21 (31.3%) were confined to a particular segment of the liver. More lesions were found to be present in the right lobe of the liver than the left lobe (16 vs 6), and a small portion (2, or 3.0% of those with location information) were located on the surface of the liver. When visualized intraoperatively, the lesions were often described as grey or white nodular lesions, with some reports also describing a cystic component.

Diagnosis, Management & Outcome

Most cases in this analysis employed biopsies as part of the diagnostic workup. Of the 112 cases for which biopsy results are available, the pathologic diagnosis was benign bile duct hamartoma in 69.6% of cases. In 8.9% of cases, the pathologic diagnosis was bile duct hamartoma with partial malignant changes, and in 21.4% of cases, the biopsy specimen was found to be consistent with malignancy.

Considering the final diagnosis reported in each case, the proportion of patients diagnosed radiologically with a malignancy was comparable to the pathology results; 26.6% of patients were diagnosed with some form of malignancy, whereas 73.3% were found to have a benign diagnosis.

Management strategies varied widely between cases. Of cases with a documented treatment approach, 59.0% proceeded with a form surgical management, most commonly partial hepatectomy. Other patients underwent cholecystectomies or liver transplants. In contrast, 36.1% of patients received supportive care. Among the patients who had received surgical intervention, 24.4% of the patients had been diagnosed with malignancies, commonly cholangiocarcinoma (14/20; 70.0%). A small portion of cases (4.8%) involved lesions found on autopsy, of which 2 patients had been diagnosed with malignancy (2/7; 28.6%).

Overall, outcomes were favorable for cases in this analysis. 116 cases reported patient outcomes; 107 cases (92.2%) reported that the patients were alive at time of publication, and 9 cases (7.8%), including those documenting lesions found on autopsy, reported that the patients were deceased at the time of publication. Outcomes were not documented for the remaining 23 cases.

DISCUSSION

Biliary duct hamartomas are benign lesions lined by bile duct epithelium and often dilated with collections of bile in their lumen.

Biliary duct hamartomas are commonly, hypoattenuating, non-enhancing lesions (Figure 2). These lesions vary in stromal characteristics and the presence of cystic dilatations of intrahepatic bile ducts covered by single layer of cuboidal cells with

intervening fibrous stroma (Figure 3). Although rare, biliary duct hamartomas pose a diagnostic challenge because of their overlapping features with malignant masses.³ Therefore, our review aimed at describing common clinical characteristics, lab evaluation and imaging findings that could help in detecting biliary hamartomas when confronted with atypical hepatic lesions. In our systematic review, 82 studies were included based on the presence of biliary duct hamartomas. These 82 studies had 139 patients with biliary duct hamartomas presenting either as a symptomatic lesion, or as an incidental finding either on imaging or intraoperatively; or as a malignant transformation.

The patients' ages ranged from 17 to 88 years, and the mean age of the patients was 55 ± 13 years. Male predominance was noted (88 male patients vs. 51 female patients). The age range in our review was comparatively greater when compared to another study that mentioned biliary duct hamartomas as a diagnosis for patients more than 35 years of age.⁷ Furthermore, males were more likely to have such a mass as compared to females. This finding also differed from a study that determined female predominance for the condition.⁷

Comorbid conditions were present in approximately half of the patients with the commonest being malignancy (12.9%), particularly gastrointestinal malignancies followed by chronic viral hepatitis B and C (8.6%). This finding corroborates previous suggestions that biliary hamartomas are not necessarily congenital in nature but can also be acquired because of viral inflammation secondary to hepatitis B and hepatitis C.³ It is, however, important to note, that this increased frequency could also be observed due to selection bias, as patients with chronic liver disease are more likely to undergo abdominal imaging.

The majority of the patients were asymptomatic (64.0%); a finding that has been reported by multiple studies.^{1, 88} The most common symptom reported by the patients was abdominal pain followed by fever, weight loss, and jaundice. However, 41 symptomatic patients (82.0%) were diagnosed with biliary duct hamartomas whereas 9 symptomatic patients (18.0%) had been diagnosed with malignancies (cholangiocarcinoma, hepatocellular carcinoma and metastatic cancer). These symptoms have also been noted in other studies.^{90, 91}

In our review, about one-third of 66 patients had elevated transaminases. Additionally, about one-fourth had hyperbilirubinemia. These elevations can suggest two possibilities; derangement in function test could occur as a result of obstruction of biliary network by a large lesion or transient damage to the lesion might manifest as the derangement.⁹² Tumor markers were reported to be normal for a majority of the 42/139 patients whose data was available (85.7%). This was similar to previous studies.³⁻⁶ However, a few exceptions were also found where CA-19, AFP, and CEA were elevated. This is most likely not specific to biliary hamartomas as elevated tumor markers are associated with many malignancies and might also be elevated in cases of underlying liver cirrhosis, portal hypertension, and jaundice.⁸⁵

Many common features were noted on ultrasonography. In most of the cases, the lesions were hypoechogenic (80%) and less than 1 cm in size (53.2%). This is an interesting finding, because a study noted that smaller lesions tend to be hyperechogenic in nature because of acoustic reflection from closely apposed walls.⁴⁰ Therefore, our findings strengthen the prior idea that ultrasonography features were mostly non-specific for biliary duct hamartoma.^{93, 94} Lesions were mostly hypointense on CT-scan. Regarding contrast, few studies report that these lesions become clearer, instead of enhancing as found in our review (32.5%), with contrast; a confusing

feature that might lead to a diagnosis of malignancy.^{95, 96} On MRI, most of the lesions produced hypointense and hyperintense signals on T1 and T2-weighted images respectively that has been mentioned in previous studies.^{95, 96} Interestingly, contrast enhancement was noted in 41.5% of the lesions, which can be attributed to compressed liver parenchyma surrounding the masses.⁷⁷

Biliary duct hamartomas were usually found distributed randomly on the surface of the liver (32.8%) but were also confined to a segment (31.5%). The right lobe was more involved than the left lobe. The reason for the difference in the involvement of lobes is not known. However, diffuse distribution of nodules on the surface of the liver was considered a feature suggestive of a benign form of biliary duct hamartomas.⁹⁵

The best diagnostic tool was, indeed, a biopsy, performed in 112 patients. The majority of the patients had a benign pathological diagnosis of biliary duct hamartomas (73.3%) but 59.9% still underwent some form of surgical procedure for management.

As mentioned in many studies, the outcomes were generally favorable with many patients surviving long-term unless they had other conditions that could potentially aggravate their condition in the long run.^{1, 92} This is true of hamartomas across organ systems—hamartomas of the lungs, small bowel and pancreas have been reported to have generally favorable outcomes.⁹⁶⁻⁹⁸ Apart from the negligible risk of malignant transformation, biliary hamartomas are a benign condition with no known long-term adverse outcomes. Consequently, no intervention is required in an asymptomatic patient.¹

A major strength of this review is the high number of patients, which allowed for a thorough analysis of the clinical, diagnostic, and prognostic features of biliary duct hamartomas. One potential limitation is publication bias—cases that involve significant or unusual

symptoms or that are associated with malignant transformation are more likely to be reported in the literature than clinically inconsequential cases.

CONCLUSION:

In summary, this systematic review of 82 studies and 139 patients represents the largest cohort of patients with biliary duct hamartomas evaluated to date. Biliary duct hamartomas can be associated with mild symptoms and lab derangements. Despite being detectable on imaging, findings are non-specific and might necessitate the use of biopsy. Currently, there are no published guidelines regarding the management of biliary duct hamartomas, and many patients have undergone surgical management despite the clinically benign nature of these malformations. Further inquiry is necessary to define the optimal management of this uncommon condition.

REFERENCES

1. Lanser HC, Puckett Y. Biliary Duct Hamartoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 16, 2021.
2. Barboi O, Moisii L, Albu-Soda A, et al. Biliary Hamartoma. *Clujul Med.* 2013; 86.
3. Abraham S, Torbenson M. Von-Meyenburg complexes increase with age and are specifically associated with alcoholic cirrhosis and end-stage hepatitis B infection. *Lab Invest.* 2006; 266A:86.
4. Redston M, Wanless I. The hepatic von Meyenburg complex: prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected] [published correction appears in *Mod Pathol* 1996; 9(7):803]. *Mod Pathol.* 1996:233-237.
5. Chung EB. Multiple bile-duct hamartomas. *Cancer.* 1970; 26:287-296.

6. Sri keerthi K, Srinivasan S, Khadatkar A, et al. Multiple Biliary Hamartoma Masquerading Polycystic Liver Disease-A Case Report. *Int J Radiology*. 2020; 7: 234-236.
7. Lin S, Weng Z, Xu J, et al. A study of multiple biliary hamartomas based on 1697 liver biopsies. *Eur J Gastroenterol Hepatol*. 2013; 25:948-952.
8. Song JS, Lee YJ, Kim KW, et al. Cholangiocarcinoma arising in von Meyenburg complexes: report of four cases. *Pathol Int*. 2008; 58:503-512.
9. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. *BMJ Evid Based Med*. 2018; 23:60-63.
10. Bailador Andrés MC, Vivas Alegre S, Rueda Castañón R. Multiple bile-duct hamartomas (Von Meyenburg complexes). *Rev Esp Enferm Dig*. 2006; 98:306-307.
11. Beard RE, Yee EU, Morteale KJ, et al. Multicystic biliary hamartoma: A report of a rare entity and a review of the literature. *Int J Surg Case Rep*. 2014; 5:919-923.
12. Bieze M, Verheij J, Phoa SS, et al. Von Meyenburg complexes mimicking metastatic disease at laparotomy for focal nodular hyperplasia. *BMJ Case Rep*. 2013; 2013:bcr2013010250.
13. Brunner P, Baudeau C, Mainguene C, et al. Magnetic resonance imaging of von Meyenburg complexes: report of a pathologically documented case. *Magn Reson Imaging*. 1994; 12(6):969-973.
14. Del Nero L, Mazza F, Cittadini G, et al. Starry Liver: An Unexpected Diagnosis. *ACG Case Rep J*. 2015; 2:77-78.

15. Dilli A, Ayaz UY, Yüksel I, et al. Computed tomography and magnetic resonance imaging findings in a case with biliary microhamartomas. *Case Rep Med.* 2012; 2012:976078.
16. Fritz S, Hackert T, Blaker H, et al. Multiple von Meyenburg complexes mimicking diffuse liver metastases from esophageal squamous cell carcinoma. *World J Gastroenterol.* 2006; 12:4250-4252.
17. Fuks D, Le Mouel JP, Chatelain D, et al. A Pitfall in the Diagnosis of Unresectable Liver Metastases: Multiple Bile Duct Hamartomas (von Meyenburg Complexes). *Case Rep Gastroenterol.* 2009; 3:198-201.
18. Gil-Bello D, Ballesteros E, Sanfeliu E, et al. Calcification in biliary hamartomatosis. *Br J Radiol.* 2012; 85:e99-101.
19. Gong J, Kang W, Xu J. MR imaging and MR Cholangiopancreatography of multiple biliary hamartomas. *Quant Imaging Med Surg.* 2012; 2:133-134.
20. Guiu B, Guiu S, Loffroy R, et al. Multiple biliary hamartomas mimicking diffuse liver metastases. *Dig Surg.* 2009; 26:209.
21. Gupta A, Pattnaik B, Das A, et al. Von Meyenburg complex and complete ductal plate malformation along with Klatskin tumour: a rare association. *BMJ Case Rep.* 2016; 2016:10.1136/bcr-2016-215220.
22. Gupta V, Makharia G. Von Meyenburg complexes in a patient with obstructive jaundice. *Med J Aust.* 2017; 207:239.
23. Hasebe T, Sakamoto M, Mukai K, et al. Cholangiocarcinoma arising in bile duct adenoma with focal area of bile duct hamartoma. *Virchows Arch.* 1995; 426:209-213.
24. Hashimoto M, Ouchi M, Norose J, et al. Bile duct hamartomas (von Meyenburg complexes) associated with a bacterial infection: case report of elderly diabetic patient. *Geriatr Gerontol Int.* 2011; 11:534-536.

25. Heinke T, Pellacani LB, Costa Hde O, et al. Hepatocellular carcinoma in association with bile duct hamartomas: report on 2 cases and review of the literature. *Ann Diagn Pathol.* 2008; 12:208-211.
26. Jain D, Sarode VR, Abdul-Karim FW, et al. Evidence for the neoplastic transformation of Von-Meyenburg complexes. *Am J Surg Pathol.* 2000; 24:1131-1139.
27. Jain D, Nayak NC, Saigal S. Hepatocellular carcinoma arising in association with von-Meyenburg's complexes: an incidental finding or precursor lesions? A clinicopathologic study of 4 cases. *Ann Diagn Pathol.* 2010; 14:317-320.
28. Jang MH, Lee YJ, Kim H. Intrahepatic cholangiocarcinoma arising in Caroli's disease. *Clin Mol Hepatol.* 2014; 20:402-405.
29. Jáquez-Quintana JO, Reyes-Cabello EA, Bosques-Padilla FJ. Multiple Biliary Hamartomas, The "Von Meyenburg Complexes". *Ann Hepatol.* 2017; 16:812-813.
30. Blanc JF, Bernard PH, Carles J, et al. Cholangiocarcinoma arising in Von Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis. *Eur J Gastroenterol Hepatol.* 2000; 12:233-237.
31. Krahn JF, Bönhof JA, Förster C, et al. Von Meyenburg complexes: a rare cause for multiple hepatic lesions on transabdominal ultrasound. *J Clin Ultrasound.* 2012; 40:174-175.
32. Kim HK, Jin SY. Cholangiocarcinoma arising in von Meyenburg complexes. *Korean J Hepatol.* 2011; 17:161-164.
33. Kim YW, Park YK, Park JH, et al. A case with intrahepatic double cancer: hepatocellular carcinoma and cholangiocarcinoma associated with multiple von Meyenburg complexes. *Yonsei Med J.* 1999; 40:506-509.

34. Koay DSC, Leow WQ, Tan TT, et al. Recurrent hepatobiliary sepsis in a patient with von Meyenburg complexes: a case report and review of the literature. *Proceedings of Singapore Healthcare*. 2017; 26:133-136.
35. Kobayashi A, Takahashi S, Hasebe T, et al. Solitary bile duct hamartoma of the liver. *Scand J Gastroenterol*. 2005; 40:1378-1381.
36. Li WH, Tsang YW, Cheung MT. Cholangiocarcinoma arising from bile duct hamartoma. *Surg Pract*. 2009; 13: 83-85.
37. Li QQ, Guo XZ, Li HY, et al. Portal hypertension in a patient with biliary hamartomas: A case report. *World J Clin Cases*. 2020; 8:1745-1751.
38. Lin S, Shang TY, Wang MF, et al. Polycystic kidney and hepatic disease 1 gene mutations in von Meyenburg complexes: Case report. *World J Clin Cases*. 2018;6:296-300.
39. Liu CH, Yen RF, Liu KL, et al. Biliary hamartomas with delayed 99mTc-diisopropyl iminodiacetic acid clearance. *J Gastroenterol*. 2005; 40:540-544.
40. Liu S, Zhao B, Ma J, et al. Lesions of biliary hamartomas can be diagnosed by ultrasonography, computed tomography and magnetic resonance imaging. *Int J Clin Exp Med*. 2014; 7:3370-3377.
41. Lung PF, Jaffer OS, Akbar N, et al. Appearances of von meyenburg complex on cross sectional imaging. *J Clin Imaging Sci*. 2013; 3:22.
42. Madakshira MG, Pandey T, Das A. von Meyenburg Complex. *Autops Case Rep*. 2019; 9:e2019107.

43. Madhusudhan KS, Das CJ. von Meyenburg's complex in a patient with primary malignancy: role of MRI. *Indian J Surg.* 2009; 71:98-100.
44. Madigan CG, Wang JY. Cirrhosis in an Active Duty Soldier With Concomitant Isolated Polycystic Disease and H63D Homozygosity. *Mil Med.* 2016; 181:e965-967.
45. Manjunath S, Hock YL, Cunningham AR. A rare but important cause of focal hepatic lesions. *Postgraduate Medical Journal* 1999; 75:567-569.
46. Mansour S, Hou D, Rattan R, et al. Non-alcoholic steatohepatitis mimicking liver metastasis in obesity surgery. *Dig Endosc.* 2011; 23:316-318.
47. Merkley SA, Sum J, Bouneva I. A Case of Multiple Bile Duct Hamartomas (Von Meyenburg Complexes) with Suspicion for Malignant Transformation: 362. *Am J Gastroenterol.* 2005; 100: S142-143.
48. Michalakis K, Coppack SW, Koak Y. Von Meyenburg complex in a bariatric patient. *J Gastrointestin Liver Dis.* 2011; 20:120.
49. Mimatsu K, Oida T, Kawasaki A, et al. Preoperatively undetected solitary bile duct hamartoma (von Meyenburg complex) associated with esophageal carcinoma. *Int J Clin Oncol.* 2008; 13:365-368.
50. Miura H, Kitamura S, Yamada H. A variant form of autoimmune pancreatitis successfully treated by steroid therapy, accompanied by von Meyenburg complex. *World J Gastroenterol.* 2009; 15:622-627.
51. Nagano Y, Matsuo K, Gorai K, et al. Bile duct hamartomas (von Mayenburg complexes) mimicking liver metastases from bile duct cancer: MRC findings. *World J Gastroenterol.* 2006;12:1321-1323.

52. Nasr D, Bidot ML, Roche M, et al. Maladie des complexes de von Meyenburg (micro-hamartomes biliaires) découverte lors d'une chirurgie laparoscopique: à propos de deux observations [Von Meyenburg disease found during laparoscopic surgery: report of two cases]. *Ann Chir.* 2006; 131:468-470.
53. Neri S, Mauceri B, Cilio D, et al. Biliary hamartomas (von Mayenburg complex): magnetic resonance imaging in a case report. *Intern Med J.* 2004; 34:71-72.
54. Neto AG, Dainiak C, Qin L, et al. Intraductal papillary cholangiocarcinoma associated with von Meyenberg complexes: a case report. *Dig Dis Sci.* 2007; 52:2643-2645.
55. Neubert Z, Mirhoseni N, Lawson RD. A starry sky liver: Klebsiella pneumoniae septic shock caused by infected multiple biliary hamartomas. *Gastrointest Endosc.* 2020; 91:1205-1207.
56. Panaro F, Gauff G, Dong G, et al. Images of interest. Hepatobiliary and pancreatic: multiple biliary hamartomas (von Meyenburg complex). *J Gastroenterol Hepatol.* 2004; 19:463.
57. Panda N, Brackett D, Eymard C, et al. Liver Transplantation for Recurrent Cholangitis From Von Meyenburg Complexes. *Transplant Direct.* 2019; 5:e428.
58. Parekh V, Reddy S, Peker D. Histologic Glimpse to Cholangiocarcinoma Arising in Von-Meyenburg Complexes: Report of a Rare Case. *Am J Clin Pathol.* 2013; 140 suppl_1: A107.

59. Park MS, Yu JS, Lee JH, et al. Value of manganese-enhanced T1- and T2-weighted MR cholangiography for differentiating cystic parenchymal lesions from cystic abnormalities which communicate with bile ducts. *Yonsei Med J.* 2007; 48(6):1072-1074.
60. Pinho AC, Melo RB, Oliveira M, et al. Adenoma-carcinoma sequence in intrahepatic cholangiocarcinoma. *Int J Surg Case Rep.* 2012; 3:131-133.
61. Röcken C, Pross M, Brucks U, et al. Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). *Arch Pathol Lab Med.* 2000; 124:1704-1706.
62. Saidi RF, Yoon V, Jabbour N, et al. Liver transplantation from a donor with multiple biliary hamartomata. *Int J Organ Transplant Med.* 2013; 4:35-37.
63. Sato S, Watanabe H, Asano T, et al. Biliary hamartomas (von Meyenburg complex) complicated with microscopic polyangiitis. *Mod Rheumatol.* 2013; 23(3):611-613.
64. Sato Y, Mukai M, Sasaki M, et al. Intraductal papillary-mucinous neoplasm of the pancreas associated with polycystic liver and kidney disease. *Pathol Int.* 2009; 59:201-204.
65. Schlachterman A, Hussain J, Firpi R. Biliary duct hamartomas in polycystic liver disease. *BMJ Case Rep.* 2015; 2015:bcr2015211141.
66. Sharma BB, Sharma S, Sharma S, et al. von Meyenburg complex (VMC) – A case report. *Indian Journal of Medical Specialities* 2016; 7: 132-134.

67. Shi QS, Xing LX, Jin LF, et al. Imaging findings of bile duct hamartomas: a case report and literature review. *Int J Clin Exp Med.* 2015; 8:13145-13153.
68. Shin YM. Biliary hamartoma presented as a single mass. *Korean J Hepatol.* 2011; 17(4):331-334.
69. Shirazi N, Chauhan NV, Chandra S, et al. Von Meyenburg complex clinically presenting as metastatic liver nodule: A rare finding in an elderly male. *J Lab Physicians.* 2019; 11: 385-387.
70. Sinakos E, Papalavrentios L, Chourmouzi D, et al. The clinical presentation of Von Meyenburg complexes. *Hippokratia.* 2011; 15:170-173.
71. Singh Y, Cawich SO, Ramjit C, et al. Rare liver tumor: symptomatic giant von Meyenburg complex. *J Surg Case Rep.* 2017; 2016:rjw195.
72. Sugawara T, Shindoh J, Hoshi D, et al. Intrahepatic cholangiocarcinoma and portal hypertension developing in a patient with multicystic biliary microhamartomas. *Malays J Pathol.* 2018; 40:331-335.
73. Suzuki H, Tsurita G, Ishihara S, et al. Resovist-enhanced MRI for preoperative assessment of colorectal hepatic metastases: a case of multiple bile duct hamartomas associated with colon cancer. *Case Rep Gastroenterol.* 2008; 2:509-516.
74. Swinnen LM, Sainte T, Verbeeck G. Multiple bile duct hamartomas simulating liver metastases on US and CT: case report. *Eur Radiol.* 1995; 5: 558-560.
75. Tarar O, Arif S, Acharya S, et al. Multiple Biliary Hamartomas in a Patient With Liver Cirrhosis: 725. *Am J Gastroenterol.* 2015; 100: S318

76. Teng SL, Shin JS, Huang JC. An unusual polynodular liver disease: Multiple biliary hamartoma. *Advances in Digestive Medicine* 2015; 2: 37-40.
77. Tohmé-Noun C, Cazals D, Noun R, et al. Multiple biliary hamartomas: magnetic resonance features with histopathologic correlation. *Eur Radiol.* 2008; 18:493-499.
78. Turdean S, Turcu M, Varga AF, et al. The Von Meyenburg complexes. *Acta Medica Marisiensis* 2011; 57: 381-383.
79. van Baardewijk LJ, Idenburg FJ, Clahsen PC, Möllers MJ. Von meyenburg-complexen in de lever: geen metastasen [Von Meyenburg complexes in the liver: not metastases]. *Ned Tijdschr Geneesk.* 2010; 154:A1674.
80. Van Dorpe J, Hackx M. Typical US, CT and MR Findings in Multiple Biliary Hamartomas. *J Belg Soc Radiol.* 2017; 101:4.
81. Varotti G, Grillo F, Fontana I. Multiple Bile Duct Hamartomas. *J Gastrointest Surg.* 2017; 21:1750-1751.
82. Vitule LF, Simionato FM, Melo ML, et al. Von Meyenburg complex: case report and literature review. *Radiol Bras.* 2010; 43: 408-410.
83. Walędziak M, Różańska-Walędziak A, Kowalewski PK, et al. Intrahepatic cholangiocarcinoma in an obese patient qualified for laparoscopic bariatric surgery - a case study. *Wideochir Inne Tech Maloinwazyjne.* 2018; 13:257-259.
84. Xu AM, Xian ZH, Zhang SH, et al. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature. *Eur J Gastroenterol Hepatol.* 2009; 21:580-584.
85. Yang XY, Zhang HB, Wu B, et al. Surgery is the preferred treatment for bile duct hamartomas. *Mol Clin Oncol.* 2017; 7:649-653.

86. Yoh T, Okamura R, Nakayama H, et al. Multicystic biliary hamartoma mimicking intrahepatic cholangiocarcinoma: report of a case. *Clin J Gastroenterol*. 2014; 7:418-421.
87. Yoshida S, Kurokohchi K, Ueno T, et al. Hepatic von Meyenburg complex: a trigger of severe portal hypertension. *Liver Int*. 2009; 29:614-615.
88. Zheng RQ, Zhang B, Kudo M, et al. Imaging findings of biliary hamartomas. *World J Gastroenterol*. 2005; 11:6354-6359.
89. Zimpfer A, Nebel B, Terracciano L. Intrahepatic cholangiocellular carcinoma associated with von Meyenburg complexes: case report and review of literature. *Diagnostic Pathology*. 2007; 2: S10.
90. Tan A, Shen JF, Hen AH. Sonogram of multiple bile duct hamartomas. *J Clin Ultrasound*. 1989; 17:667–669.
91. Shu-Chen W, Guan-Tarn H, Chien-Hung C, et al. Bile duct hamartomas: A report of two cases. *J Clin Gastroenterol*. 1997; 25:608–611.
92. Yamada N, Sanada Y, Katano T, et al. Pediatric living donor liver transplantation for congenital hepatic fibrosis using a mother's graft with von Meyenburg complex: A case report. *World J Gastroenterol*. 2016; 22:9865-9870.
93. Wohlgemuth WA, Böttger J, Bohndorf K. MRI, CT, US and ERCP in the evaluation of bile duct hamartomas (von Meyenburg complex): a case report. *Eur Radiol*. 1998; 8:1623-1626.
94. Erlinger S. Low phospholipid-associated cholestasis and cholelithiasis. *Clin Res Hepatol Gastroenterol*. 2012; 36 Suppl 1:S36-40.
95. Pech L, Favelier S, Falcoz MT, et al. Imaging of Von Meyenburg complexes. *Diagn Interv Imaging*. 2016; 97:401-409.

96. Gjevre JA, Myers JL, Prakash UB. Pulmonary hamartomas. *Mayo Clin Proc.* 1996; 71:14-20.
97. Kawakami F, Shimizu M, Yamaguchi H, et al. Multiple solid pancreatic hamartomas: A case report and review of the literature. *World J Gastrointest Oncol.* 2012; 4:202-206.
98. Levine JA, Burgart LJ, Batts KP, et al. Brunner's Gland Hamartomas: Clinical Presentation and Pathological Features of 27 Cases. *Am J Gastroenterol.* 1995; 90:290-294.

Figure Legends:

Figure 1: PRISMA flow chart

Figure 2: CT Abdomen Pelvis with contrast showing 1.1 cm hypodense lesion within segment IVb

Figure 3: Liver parenchyma showing a well-demarcated lesion with small to medium sized, irregularly shaped dilated glands lined by bland cuboidal epithelium with intervening fibrous stroma and surrounding inflammatory cells consistent with biliary hamartomas (H&E, x20)

Table 3: Demographic characteristics of the cases reviewed

Article	Age	Sex	Comorbidities			Time to presentation
			Hepatitis B	Hepatitis C	Cancer	
Andres et al ¹⁰	50	M	-	-	-	NA
Barboi et al ²	71	M	-	-	-	NA
Beard et al ¹¹	48	F	-	Positive	-	NA
Bieze et al ¹²	44	F	-	-	-	NA
Brunner et al ¹³	65	F	-	-	-	NA
Del Nero et al ¹⁴	65	M	-	-	-	NA
Dilli et al ¹⁵	61	F	-	-	-	NA
Fritz et al ¹⁶	66	M	-	-	Esophageal carcinoma	NA
	47	M	-	-	Esophageal carcinoma	
Fuks et al ¹⁷	56	F	-	-	Breast cancer	10 years
Gil Bello et al ¹⁸	56	M	-	-	Prostate cancer	NA
Gong et al ¹⁹	57	M	-	-	-	Several years
Guiu et al ²⁰	53	F	-	-	Breast cancer	NA
Gupta et al ²¹	53	M	-	-	-	1 month
Gupta et al ²²	33	M	-	-	-	NA
Hasebe et al ²³	59	M	-	-	Sigmoid colon cancer	NA

Article	Age	Sex	Comorbidities			Time to presentation
			Hepatitis B	Hepatitis C	Cancer	
Hashimoto et al ²⁴	75	M	-	-	-	NA
Heinke et al ²⁵	19	F	-	-	-	NA
	39	M	-	-	-	
Jain et al ²⁶	63	M	-	-	-	NA
	81	M	-	Positive	-	
	66	F	-	-	Breast cancer	
Jain et al ²⁷	55-60	4 M	-	Positive x2	-	NA
Jang et al ²⁸	44	F	-	-	-	NA
Jáquez-Quintana et al ²⁹	50	M	-	-	-	NA
JF Blanc et al ³⁰	61	M	-	-	-	NA
JF Krahm et al ³¹	52	F	-	-	-	NA
Kim et al ³²	66	M	-	-	-	NA
Kim et al ³³	74	M	-	-	-	NA
Koay et al ³⁴	62	M	-	-	-	7 years
Kobayashi et al ³⁵	30	M	-	-	-	NA
Li et al ³⁶	71	F	Positive	-	-	NA

Li et al ³⁷	40	M	-	-	-	1 day
Lin et al ³⁸	62 57	F F	Positive x2	-	-	NA
Lin et al ⁷	17-63	4 M 2 F	Positive x1	-	-	NA
Liu et al ³⁹	61	M	-	-	-	NA
Liu et al ⁴⁰	28-66	5 M 7 F	Positive x3	-	Gastric cancer x2 Colorectal cancer x3 Thyroid cancer x1 Lung cancer x1	NA
Lung et al ⁴¹	81	M	-	-	-	1 week
Madakshira et al ⁴²	50	M	-	-	-	NA
Madhusudhan et al ⁴³	61	M	-	-	-	1 month
Madigan et al ⁴⁴	45	M	-	-	-	NA
Manjunath et al ⁴⁵	57	M	-	-	-	3 months
Mansour et al ⁴⁶	51	F	-	-	-	NA
Merkley et al ⁴⁷	71	F	-	-	-	5 years
Michalakis et al ⁴⁸	54	M	-	-	-	NA
Mimatsu et al ⁴⁹	60	M	-	-	-	1 year
Miura et al ⁵⁰	55	M	-	-	-	1 week

Nagano et al ⁵¹	76	M	-	-	Common bile duct cancer	NA
Nasr et al ⁵²	45	M	-	-	-	NA
Neri et al ⁵³	51	M	-	-	-	NA
Neto et al ⁵⁴	70	F	-	Positive	-	3 weeks
Neubert et al ⁵⁵	52	F	-	-	-	3 months
Panaro et al ⁵⁶	55	M	-	-	-	NA
Panda et al ⁵⁷	62	F	-	-	-	NA
Parekh et al ⁵⁸	76	F	-	-	-	NA

Article	Age	Sex	Comorbidities			Time to presentation
			Hepatitis B	Hepatitis C	Cancer	
Park et al ⁵⁹	53	M	-	-	-	NA
Pinho et al ⁶⁰	56	F	-	-	-	2 months
Rocken et al ⁶¹	59	F	-	-	-	NA
Saidi et al ⁶²	49	F	-	-	-	NA
Sato et al ⁶³	59	M	-	-	-	1 year
Sato et al ⁶⁴	63	M	-	-	-	NA
Schlachterman et al ⁶⁵	45	M	-	-	-	NA
Sharma et al ⁶⁶	73	M	-	-	-	NA
Shi et al ⁶⁷	37	M	Positive	-	-	6 months
Shin et al ⁶⁸	62	F	-	-	-	NA
	79	M	-	-	Colon cancer	
Shirazi et al ⁶⁹	65	M	-	-	-	1 month
Sinakos et al ⁷⁰	25-60	2 M 2 F	-	-	-	3 days-6 months
Singh et al ⁷¹	55	M	-	-	-	NA
Song et al ⁸	59-75	4 M	Positive x1	Positive x1	-	NA
Sugawara et al ⁷²	55	M	-	-	-	3 years

Suzuki et al⁷³ 56 M - - Advanced sigmoid colon cancer NA

Article	Age	Sex	Comorbidities			Time to presentation
			Hepatitis B	Hepatitis C	Cancer	
Swinnen et al ⁷⁴	63	F	-	-	-	NA
Tarar et al ⁷⁵	57	M	-	-	-	1 week
Teng et al ⁷⁶	73	M	-	-	-	2 days
Tohme et al ⁷⁷	33-68	4 M 7 F	-	-	Gastric carcinoma x1	NA
Turdean et al ⁷⁸	66	M	-	-	-	NA
van Baardewijk ⁷⁹	74	F	-	-	-	NA
Van Dorpe et al ⁸⁰	38	F	-	-	-	NA
Varotti et al ⁸¹	63	M	NA	NA	NA	NA
Vitule et al ⁸²	27	F	-	-	-	2 days
Waledziak et al ⁸³	58	M	-	-	-	NA
Xu et al ⁸⁴	88	M	-	-	-	NA
	65	F	-	Positive	-	
Yang et al ⁸⁵	35-70	7 M 2 F	Positive x5	-	-	NA
Yoh et al ⁸⁶	69	M	-	-	-	NA

Yoshida et al ⁸⁷	88	F	-	-	-	NA
Zheng et al ⁸⁸	29-72	4 M 2 F	-	-	-	NA
Zimpfer et al ⁸⁹	73	M	-	-	-	NA

Table 4: Clinical presentation and laboratory findings of the cases reviewed.

Article	Symptoms			Labs			Clinical exam
	Abdominal pain	Jaundice	Fever	AST/ALT	GGT	Bilirubin	
Andres et al ¹⁰	-	-	-	Elevated	Elevated	-	NA
Barboi et al ²	-	-	-	-	-	-	Hepatomegaly
Beard et al ¹¹	Present	-	-	-	-	-	NA
Bieze et al ¹²	Present	-	-	Elevated	-	-	NA
Brunner et al ¹³	-	-	-	-	-	-	NA
Del Nero et al ¹⁴	-	-	-	-	Elevated	-	Hepatomegaly
Dilli et al ¹⁵	Present	-	-	-	-	-	NA
Fritz et al ¹⁶	-	-	-	NA	NA	NA	NA
Fuks et al ¹⁷	-	-	-	NA	NA	NA	NA
Gil Bello et al ¹⁸	-	-	-	-	-	-	NA
Gong et al ¹⁹	Present	-	-	Elevated ALT only	-	Elevated	NA
Guiu et al ²⁰	-	-	-	-	-	-	NA
Gupta et al ²¹	-	Present	-	Elevated	Elevated	Elevated	Jaundice, hepatomegaly
Gupta et al ²²	Present	-	-	-	-	-	NA

Hasebe et al ²³	-	-	-	-	-	-	NA
Hashimoto et al ²⁴	-	-	Present	Elevated	Elevated	-	NA
Heinke et al ²⁵	-	Present	-	-	-	-	NA
Jain et al ²⁶	Present x2	-	-	Elevated ALT only x1	-	-	Splenomegaly x2, ascites x2, varices x1, portal HTN x1
Article	Symptoms			Labs			Clinical exam
	Abdominal pain	Jaundice	Fever	AST/ALT	GGT	Bilirubin	
Jain et al ²⁷	Present x2	-	Present x1	-	-	-	NA
Jang et al ²⁸	-	-	-	-	-	Elevated	NA
Jáquez-Quintana et al ²⁹	-	-	-	Elevated AST only	Elevated	-	NA
JF Blanc et al ³⁰	-	-	-	-	Elevated	-	NA
JF Krahn et al ³¹	-	-	-	-	Elevated	-	HTN
Kim et al ³²	-	-	-	-	Elevated	-	NA
Kim et al ³³	-	-	-	-	-	-	NA
Koay et al ³⁴	Present	Present	Present	NA	NA	NA	Positive Murphy's sign, tenderness in RUQ
Kobayashi et al ³⁵	-	-	-	NA	NA	NA	NA

Li et al ³⁶	-	-	-	-	-	-	NA
Li et al ³⁷	-	-	-	-	-	-	NA
Lin et al ³⁸	-	-	-	Elevated x2	-	-	NA
Lin et al ⁷	-	Present x1	-	Elevated x1	-	-	NA
Liu et al ³⁹	-	-	-	-	-	-	NA
Liu et al ⁴⁰	-	-	-	-	-	-	NA
Lung et al ⁴¹	Present	-	-	-	-	-	Abdominal distension and guarding

Article	Symptoms			Labs			Clinical exam
	Abdominal pain	Jaundice	Fever	AST/ALT	GGT	Bilirubin	
Madakshira et al ⁴²	-	-	-	-	-	-	NA
Madhusudhan et al ⁴³	-	-	-	-	-	-	NA
Madigan et al ⁴⁴	-	-	-	-	-	-	Splenomegaly, gynecomastia, +1 pedal edema
Manjunath et al ⁴⁵	Present	-	-	-	-	-	Hepatomegaly
Mansour et al ⁴⁶	-	-	-	Elevated ALT only	Elevated	-	NA
Merkley et al ⁴⁷	Present	-	-	-	-	-	NA
Michalakakis et al ⁴⁸	-	-	-	-	-	-	NA
Mimatsu et al ⁴⁹	-	-	-	-	-	-	NA
Miura et al ⁵⁰	Present	Present	-	Elevated	Elevated	Elevated	Jaundice
Nagano et al ⁵¹	Present	-	-	-	-	-	NA
Nasr et al ⁵²	Present x1	-	-	-	-	-	Positive Murphy's sign x1, RUQ pain x1
Neri et al ⁵³	Present	-	-	-	-	-	Hepatomegaly
Neto et al ⁵⁴	Present	-	-	Elevated	-	-	Positive Murphy's sign, RUQ tenderness
Neubert et al ⁵⁵	-	Present	Present	-	-	Elevated	HoTN, fever, tachycardia

Panaro et al ⁵⁶	-	-	-	-	-	-	NA
Panda et al ⁵⁷	-	-	-	-	-	-	NA
Parekh et al ⁵⁸	-	-	-	-	-	-	NA

Article	Symptoms			Labs			Clinical exam
	Abdominal pain	Jaundice	Fever	AST/ALT	GGT	Bilirubin	
Park et al ⁵⁹	-	-	-	-	-	-	NA
Pinho et al ⁶⁰	-	-	-	-	-	-	NA
Rocken et al ⁶¹	Present	-	-	-	Elevated	-	NA
Saidi et al ⁶²	-	-	-	Elevated	-	-	NA
Sato et al ⁶³	-	-	Present	Elevated	-	-	Bilateral peripheral edema and distal polyneuropathy
Sato et al ⁶⁴	Present	-	-	-	-	-	NA
Schlachterman et al ⁶⁵	-	-	-	Elevated ALT only	Elevated	-	NA
Sharma et al ⁶⁶	-	-	-	-	-	-	NA
Shi et al ⁶⁷	-	-	-	NA	NA	NA	NA
Shin et al ⁶⁸	-	-	-	-	-	-	Weight loss
Shirazi et al ⁶⁹	Present	-	-	-	-	Elevated	Vague mass in the RUQ
Sinakos et al ⁷⁰	Present x4	Present x1	Present x2	Elevated x2	Elevated x1	-	RUQ tenderness x2
Singh et al ⁷¹	Present	-	-	-	-	-	Vague mass in the LUQ
Song et al ⁸	-	-	-	NA	NA	NA	NA
Sugawara et	-	-	Present	-	-	-	NA

al⁷²

Suzuki et al⁷³ - - - - - NA

Article	Symptoms			Labs			Clinical exam
	Abdominal pain	Jaundice	Fever	AST/ALT	GGT	Bilirubin	
Swinnen et al ⁷⁴	Present	-	-	NA	NA	NA	Normal physical exam
Tarar et al ⁷⁵	-	-	Present	-	-	-	NA
Teng et al ⁷⁶	Present	-	Present	-	-	-	Positive Murphy's sign, RUQ tenderness
Tohme et al ⁷⁷	-	-	-	-	Elevated	-	NA
Turdean et al ⁷⁸	Present	-	-	-	-	-	NA
van Baardewijk ⁷⁹	-	-	-	-	-	-	Friable tumor on rectal exam
Van Dorpe et al ⁸⁰	Present	-	-	-	-	-	NA
Varotti et al ⁸¹	NA	NA	NA	NA	NA	NA	NA
Vitule et al ⁸²	Present	-	-	-	-	-	NA
Waledziak et al ⁸³	-	-	-	-	-	-	NA
Xu et al ⁸⁴	Present x2	-	-	Elevated ALT only x1	Elevated x1	-	Positive Murphy's sign x1, RUQ tenderness x1

Yang et al ⁸⁵	Present x2	-	-	ALT elevated x2 and AST elevated x3	-	Elevated x2	NA
Yoh et al ⁸⁶	-	-	-	-	-	-	NA
Yoshida et al ⁸⁷	-	-	-	-	Elevated	-	NA
Zheng et al ⁸⁸	-	-	-	-	-	-	NA
Zimpfer et al ⁸⁹	-	-	-	-	-	-	NA

Table 5: Pathological findings of cases reviewed

Article	Tumor markers	Biopsy	Diagnosis	Management	Outcome
Andres et al ¹⁰	NA	NA	Biliary hamartoma	NA	Alive
Barboi et al ²	Normal	NA	Biliary hamartoma	Supportive	Alive
Beard et al ¹¹	NA	Thick, dense fibrous tissue containing cytologically bland, large-caliber bile ducts with intermingled benign hepatocytes	Biliary adenofibroma in setting of multiple biliary hamartomas	Surgical	Alive
Bieze et al ¹²	Normal	NA	Biliary hamartoma	Surgical	Alive
Brunner et al ¹³	Normal	Regular epithelium in setting of dense fibrous stroma, pericentrolobular cholestasis	Biliary hamartoma without malignancy	Surgical	Alive
Del Nero et al ¹⁴	Normal	NA	Biliary hamartoma	NA	Alive
Dilli et al ¹⁵	Normal	NA	Biliary hamartoma	Supportive	Alive
Fritz et al ¹⁶	NA	Biliary hamartomas x2	Biliary hamartoma x2	Surgical x2	Alive
Fuks et al ¹⁷	Normal	Fibrosis	Biliary hamartoma	Surgical	Alive
Gil Bello et al ¹⁸	Normal	Multiple nodules composed of multiple bile ducts; periductal fibrous stroma and fibrous bridges between nodules	Biliary hamartoma	Autopsy finding	Death
Gong et al ¹⁹	Normal	NA	Biliary hamartoma	NA	NA
Guiu et al ²⁰	Normal	Biliary epithelium with fibrous stroma	Biliary hamartoma	NA	NA
Gupta et al ²¹	Normal	Multiple biliary hamartomas with complete ductal	Biliary hamartoma with	Surgical	Alive

		plate dysgenesis	Klatskin tumor		
Gupta et al ²²	Normal	NA	Biliary hamartoma	NA	Alive
Hasebe et al ²³	Elevated CEA	Site 1: Bile duct adenoma and atypical ductules growing into the liver parenchyma, granular/hyperchromatic large nuclei. Site 2: Metastatic adenocarcinoma from sigmoid colon	Bile duct adenocarcinoma with focal area of biliary hamartoma	Surgical	Alive
Hashimoto et al ²⁴	Normal	NA	Biliary hamartoma	Supportive	Alive
Heinke et al ²⁵	Normal	Patient 1: Well-differentiated pattern with polygonal cells, vesicular nuclei, prominent nucleoli, irregular dilated bile ducts w/ fibrous stroma consistent with bile duct hamartomas. Patient 2: 3.2cm tumor w/ central fibrosis consistent with HCC and biliary hamartomas	Hepatocellular carcinoma with underlying biliary hamartomas x2	Autopsy finding x1; surgical x1	Death x1; alive x1
Jain et al ²⁶	Normal x3	Diffuse nodularity and fibrosis, numerous biliary hamartomas, ductal proliferations showing adenocarcinoma, neoplastic changes in biliary hamartoma (irregular contours, inspissated bile, hyalinized stroma) x3	Intrahepatic cholangiocarcinoma x3	Surgical x1; autopsy finding x1; NA x1	Death x2; NA x1

Article	Tumor markers	Biopsy	Diagnosis	Management	Outcome
Jain et al ²⁷	Normal	Nodular liver, HCC in largest nodule, surrounded by multiple biliary hamartomas x4	HCV-related end-stage liver disease x2; alcohol-related chronic liver disease x1; cryptogenic cirrhosis x1	Liver transplant x4	Alive x4
Jang et al ²⁸	Normal	Markedly dilated intrahepatic bile ducts, surrounded by various degrees of fibrosis and chronic active inflammation . Most of the ducts were lined by flattened cuboidal or columnar epithelium, and some dilated ducts demonstrated polypoid fibrovascular projections characteristic of ductal plate malformation. Ascending cholangitis with periductal fibrosis was seen in some smaller peripheral bile duct branches, and the bile duct mucosa were ulcerated, and the lumens filled with inflammatory exudate.	Intrahepatic cholangiocarcinoma	Surgical	Alive
Jáquez-Quintana et al ²⁹	Normal	NA	Biliary hamartoma	Surgical	Alive
JF Blanc et al ³⁰	Normal	Tumor composed of two distinct parts: 1) cholangiocarcinoma w/ biliary hamartomas, 2) moderately differentiated HCC w/ necrosis and macrotrabecular glans	Concurrent hepatocellular carcinoma and intrahepatic cholangiocarcinoma	Surgical	Alive
JF Krahn et al ³¹	NA	NA	Biliary hamartoma	NA	Alive
Kim et al ³²	Normal	Cholangiocarcinoma w/ surrounding biliary hamartomas	Intrahepatic cholangiocarcinoma	Surgical	Alive

Kim et al ³³	Normal	Well-differentiated HCC composed of proliferating bile ductules with foci of dysplastic epithelium along the dilated bile ducts, multiple foci of biliary hamartomas scattered throughout tumor	Hepatocellular carcinoma	Surgical	Alive
Koay et al ³⁴	NA	Aggregates of angulated bile ducts within a fibrous stroma, and portal fibrosis. The bile ducts within the biliary hamartomas were involved by acute inflammation with microabscess formation. Features of large duct obstruction, portal–portal bridging necrosis and ductular proliferation also present	Biliary hamartoma	Supportive	Alive
Kobayashi et al ³⁵	NA	Discrete, periportal cysts embedded in a fibrous stroma, lined by a low columnar or cuboidal epithelium and contained bile-stained material, some dilated	Biliary hamartoma	Surgical	Alive
Li et al ³⁶	Normal	NA	Cholangiocarcinoma arising from an underlying biliary hamartoma	Surgical	Alive
Li et al ³⁷	NA	NA	Biliary hamartoma	Supportive	Alive
Lin et al ³⁸	NA	Patient 1: Biliary hamartoma and changes consistent with chronic hepatitis B. Patient 2: NA	Patient 1: Hepatocellular carcinoma and biliary hamartoma; Patient 2: Biliary hamartoma	Supportive x1; NA x1	Alive
Lin et al ⁷	Normal	Dilated duct-like structures lined by a single layer of columnar or cuboidal epithelium and accompanied by a variable amount of fibrous stroma x6. Mild dysplasia of the biliary epithelium x2, a normal lobular pattern and	Biliary hamartomas x6; Hepatocellular carcinoma x1	Surgical	Alive x6

		superimposed irregular diffuse periportal fibrosis x1, moderate piecemeal necrosis plus bridging necrosis and stage 4 fibrosis x1			
Liu et al ³⁹	Normal	Expanded portal areas, with variably dilated and disorganized bile ducts, embedded in fibrous stroma, and containing altered bile. No evidence of malignancy.	Biliary hamartoma	Supportive	Alive
Liu et al ⁴⁰	Normal	Lesions were subsequently classified into class 1 (predominantly solid lesions with narrow bile channels), class 2 (intermediate, with mild or focal dilatation of bile channels), and class 3 (predominantly cystic). Class 1: 0, Class 2: 8, Class 3: 4	Biliary hamartomas x 12	NA x12	Alive x12
Lung et al ⁴¹	Normal	Normal background hepatic parenchyma. Focal lesions: expanded portal tracts with dense stroma, containing dilated bile ducts; a few of which contained inspissated bile. One dilated congested blood vessel.	Biliary hamartoma	Surgical	Alive
Article	Tumor markers	Biopsy	Diagnosis	Management	Outcome

Madakshira et al ⁴²	Normal	Bile-stained lesions, likely micro-hamartomas composed of a collection of dilated varying-sized ducts lined by cuboidal epithelium in a fibrotic stroma. The cells lining these ducts were positive for Cytokeratin 7, confirming them to be of bile duct origin	Biliary hamartoma	Autopsy finding	Death
Madhusudhan et al ⁴³	Normal	NA	Biliary hamartoma	Surgical	Alive
Madigan et al ⁴⁴	Normal	Fibrosis, hepatocellular extinction, mild iron deposition	Polycystic liver disease and biliary hamartoma	NA	Alive
Manjunath et al ⁴⁵	Normal	Dilated bile ducts lined by attenuated bland epithelium. Inspissated bile seen in one duct	Biliary hamartoma	Supportive	Alive
Mansour et al ⁴⁶	Normal	Irregularly shaped ductular structures lined by cuboidal epithelium, surrounded by dense fibrous stroma (interface between the biliary hamartoma and the liver parenchyma)	Biliary hamartoma	Supportive	Alive
Merkley et al ⁴⁷	Elevated CA-A 19	Biliary hamartoma	Biliary hamartoma	NA	Alive
Michalakis et al ⁴⁸	Normal	Intraportal proliferations of small to medium sized irregular ductuli lined by benign flattened biliary epithelium, embedded within fibrous stroma	Biliary hamartoma	NA	Alive
Mimatsu et al ⁴⁹	Normal	Multiple dilated bile ducts with surrounding fibrous stroma	Biliary hamartoma	Surgical	Alive
Miura et al ⁵⁰	Normal	Aggregation of irregular-shaped cystic dilated bile ducts embedded in fibrous stroma, with	Biliary hamartoma	NA	Alive

		minimal inflammatory reaction			
Nagano et al ⁵¹	Normal	Multiple bile ducts with slightly dilated lumens embedded in the collagenous stroma	Biliary hamartoma	Surgical	Alive
Nasr et al ⁵²	Normal	Biliary hamartoma	Biliary hamartoma x2	Surgical x1; supportive x1	Alive
Neri et al ⁵³	Normal	Periportal cysts on mono-stratified cubical epithelium and a conspicuous increase in connective tissue	Biliary hamartoma	Supportive	Alive
Neto et al ⁵⁴	Normal	Tumor within lumen of the bile duct without invasion into liver parenchyma	Intraductal papillary cholangiocarcinoma	Surgical	Alive
Neubert et al ⁵⁵	Normal	NA	Biliary hamartoma	Surgical	Alive
Panaro et al ⁵⁶	Normal	Dilated bile ducts lined by cuboidal epithelium that were embedded in a dense fibrous stroma	Biliary hamartoma	Surgical	Alive
Panda et al ⁵⁷	Normal	Biliary hamartoma without evidence of advanced fibrosis	Biliary hamartoma	NA	Alive
Parekh et al ⁵⁸	Normal	Well-differentiated cholangiocarcinoma and numerous biliary hamartomas. Tumor cells were positive for CK7 and CA19.9 with focal staining for CK20, but negative for TTF-1 and p63	Cholangiocarcinoma	Surgical	Alive
Article	Tumor markers	Biopsy	Diagnosis	Management	Outcome

Park et al ⁵⁹	Normal	NA	Biliary hamartoma	NA	Alive
Pinho et al ⁶⁰	Normal	Bile duct adenoma	Intrahepatic cholangiocarcinoma in the setting of bile duct adenomas	Surgical	Alive
Rocken et al ⁶¹	Normal	Non-encapsulated tumor with columnar/cuboidal cells with necrosis, likely poorly differentiated adenocarcinoma. Liver nodules scattered throughout found to be biliary hamartomas	Intrahepatic cholangiocarcinoma	Surgical	Alive
Saidi et al ⁶²	Normal	NA	Biliary hamartomas	NA	Alive
Sato et al ⁶³	Normal	NA	Biliary hamartoma	NA	Alive
Sato et al ⁶⁴	Normal	Hepatic cysts lined by cuboidal, flattened biliary □ type epithelium without atypia	Biliary hamartoma	NA	Alive
Schlachterman et al ⁶⁵	Normal	Biliary hamartomas and features of ductal plate malformation	Biliary hamartomas	NA	Alive
Sharma et al ⁶⁶	Normal	NA	Biliary hamartomas	NA	Alive
Shi et al ⁶⁷	NA	Irregularly-arrangement small bile ducts surrounded by fibrocollagenous stroma. The bile duct epithelia were significantly hyperplastic without cellular heteromorphism	Biliary hamartoma	Supportive	Alive
Shin et al ⁶⁸	Normal	Patient 1: Biliary hamartoma with cystic dilation. Patient 2: NA	Biliary hamartoma	NA x1; surgical x1	Alive

Shirazi et al ⁶⁹	Normal	Partial effacement of lobular architecture. Many proliferating bile ducts lined by the single layer of uniform cuboidal epithelium without mitotic activity. Mild-to-moderate fibrosis around these ductules.	Biliary hamartoma	Supportive	Alive
Sinakos et al ⁷⁰	NA x2, Normal x2	NA	Biliary hamartoma	NA x2; supportive x2	Alive
Singh et al ⁷¹	Normal	Cyst wall composed of loose collagenous tissue lined by a single layer of cuboidal cells in keeping with biliary type epithelium. The adjacent liver parenchyma contained several ectatic bile ducts with focal branching. The surrounding stroma was densely hyalinized with a mild lymphocytic infiltrate and dilated lymphatic channels	Biliary hamartoma and cyst	Surgical	
Song et al ⁸	Elevated CA-A 19 x1, NA x3	Tumor composed of benign biliary hamartomas characterized by irregular and dilated ducts without luminal bile. Multiple foci of adenocarcinoma consisting of infiltrative and dysplastic glandular/solid structures. Dysplasia shown as pseudostratification comprising cells with enlarged and variably sized nuclei and some apical snouts x3; fibrocystic liver disease x1	Metastatic colon cancer with biliary hamartoma x2; presumed “unusual type of hepatocellular carcinoma or hemangioma with biliary hamartoma x1; hepatic adenocarcinoma with biliary hamartoma x1	Surgical x4	Death x1; alive x3
Sugawara et al ⁷²	Elevated CA-A 19	Intrahepatic cholangiocarcinoma with diffuse microhamartomas and dilated/irregular hyperplastic bile ducts	Cholangiocarcinoma with concurrent biliary hamartoma	Surgical	Alive
Suzuki et al ⁷³	Normal	NA	Biliary hamartoma	Supportive	Alive

Article	Tumor markers	Biopsy	Diagnosis	Management	Outcome
---------	---------------	--------	-----------	------------	---------

Swinnen et al ⁷⁴	Normal	Multiple, tortuous, dilated bile ducts, lined with normal cuboidal epithelium and embedded in a fibrous stroma	Biliary hamartoma	Supportive	Alive
Tarar et al ⁷⁵	Normal	NA	Biliary hamartoma	Supportive	Alive
Teng et al ⁷⁶	Normal	Multiple biliary channels lined by the regular cuboidal epithelium with dense fibrous stroma	Biliary hamartoma	Supportive	Alive
Tohme et al ⁷⁷	Normal	3-6mm cysts lined with regular cubic flattened epithelium. Most of them contained an endocystic polypoid projection made of portal collagenous tissue without epithelial hyperplasia. Adjacent to the cysts, biliary hamartomas were variably dilated, and cystic ducts had irregular outlines creating endocystic collagenous prolapsus. One patient presented with a 2-cm, moderately differentiated cholangiocarcinoma in the left lobe. Numerous preserved biliary hamartomas sustained by hyalinized collagenous stroma were observed inside the tumor, some of them were malignant.	Biliary hamartoma x9; cholangiocarcinoma x1	NA	Alive x11
Turdean et al ⁷⁸	Normal	Bile ducts were lined with simple columnar epithelium, focally flattened, without nuclear atypia. The luminal content was amorphous, slightly eosinophilic, and negative to the Alcian blue-PAS stain. The stroma between these ducts was dense, rich in collagen fibers, and was continued by the stroma of adjacent portal areas. A reduced quantity of interstitial Alcian blue-positive mucin was also present	Biliary hamartoma	Surgical	Alive

van Baardewijk ⁷⁹	Normal	Biliary hamartomas	Biliary hamartoma	NA	Alive
Van Dorpe et al ⁸⁰	Normal	NA	Biliary hamartomas	NA	Alive
Varotti et al ⁸¹	Normal	NA	Biliary hamartoma	Surgical	Alive
Vitule et al ⁸²	Normal	Cystic dilations involving granulomatous fibrotic tissue of intrahepatic biliary ducts	Biliary hamartomas	Surgical	Alive
Waledziak et al ⁸³	Normal	Initial resected tumor: Low-grade intrahepatic cholangiocarcinoma without vascular invasion, CK7+, CK19+, CK20-, p53+, PAS-, CK20-. Subsequent right hepatectomy: focal bile duct hamartoma w/o signs of malignancy	Low-grade intrahepatic cholangiocarcinoma	Surgical	Alive
Xu et al ⁸⁴	Elevated AFP and CA-A19 x1, Normal x1	Tumor with areas of dysplastic ductal cells consistent with adenocarcinoma that appear to transition from mild dysplasia to invasive, inflammatory infiltrates with lymph follicles in connective tissue, necrosis present x2; cavitation lesions x1	Intrahepatic cholangiocarcinoma x2	Surgical x2	Death x2
Yang et al ⁸⁵	Normal	Bile duct proliferation x6; Bile duct proliferation, partly nest-like arrangement x1; Bile duct proliferation, partly nest-like arrangement, liver cirrhosis x1; Obvious atypical cells, invasive growth, partly bile duct proliferation, cholangiocarcinoma x1	Biliary hamartomas x6; Biliary duct hamartomas with partial malignant transformation x3	NA	Alive x8
Yoh et al ⁸⁶	Normal	Multicystic mass consisting of dilated cystic bile ducts, periductal glands, connective tissue, and blood vessels with thickened walls. Findings consistent with biliary hamartoma, suggestive of multicystic biliary hamartoma	Multicystic biliary hamartoma	Surgical	Alive
Yoshida et al ⁸⁷	Normal	Diffuse bile duct hamartomas. H&E staining showed bile duct microhamartomas consisting of	Biliary hamartoma and portal HTN	Supportive	Alive

		circumscribed fibrous areas containing many irregularly dilated bile duct structures and only a few narrowed vessels in the portal region.			
Zheng et al ⁸⁸	Normal	Multiple dilated bile ducts lined by a single layer of cubic epithelium x2	Biliary hamartoma x5	NA	Alive x5
Zimpfer et al ⁸⁹	Normal	Multiple dilated bile ducts, some containing bile plugs, small glandular units lined by cuboidal cells with marked atypia, dense desmoplastic stroma and invaded the liver parenchyma. CK7+	Intrahepatic cholangiocarcinoma and biliary hamartoma	NA	NA

Identification

Records identified through
database searching
(n = 163)

Additional records identified through
other Web of Science (n=33),
CINHAL (n = 63)

Screening

Records after duplicates removed
(n = 198)

Records screened
(n =198)

Records excluded
(n = 107)

Eligibility

Full-text articles assessed
for eligibility
(n =91)

Full-text articles excluded,
with reasons
(n =9)

1. Inaccessible article (n=5)
2. No information in article (n=3)
3. Article requested from author but received no response (n=1)

Studies included in
qualitative synthesis
(n =82)

Included

Systematic review done